Integrated Transcriptomic and Proteomic Study of the Mechanism of Action of the Novel Small-Molecule Positive Allosteric Modulator 1 in Targeting PAC1-R for the Treatment of D-Gal-Induced Aging Mice
International Journal of Molecular Sciences · 2024
DOI: 10.3390/ijms25073872 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Lili Liang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cell Biology, College of Life Science and Technology, Jinan University, Guangzhou 510632, China. Hauptthemen laut MEDLINE: Transcriptome, Proteomics. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Guangdong Province.
Abstract (Originalsprache)
Small-molecule positive allosteric modulator 1 (SPAM1), which targets pituitary adenylate cyclase-activating polypeptide receptor 1 (PAC1-R), has been found to have a neuroprotective effect, and the underlying mechanism was explored in this study. First, using a D-galactose (D-gal)-induced aging mouse model, we confirmed that SPAM1 improves the structure of the hippocampal dentate gyrus and restores the number of neurons. Compared with D-gal model mice, SPAM1-treated mice showed up-regulated expression of Sirtuin 6 (SIRT6) and Lamin B1 and down-regulated expression of YinYang 1 (YY1) and p16. A similar tendency was observed in senescent RGC-5 cells induced by long-term culture, indicating that SPAM1 exhibits significant in vitro and in vivo anti-senescence activity in neurons. Then, using whole-transcriptome sequencing and proteomic analysis, we further explored the mechanism behind SPAM1’s neuroprotective effects and found that SPAM is involved in the longevity-regulating pathway. Finally, the up-regulation of neurofilament light and medium polypeptides indicated by the proteomics results was further confirmed by Western blotting. These results help to lay a pharmacological network foundation for the use of SPAM1 as a potent anti-aging therapeutic drug to combat neurodegeneration with anti-senescence, neuroprotective, and nerve regeneration activity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cell Biology, College of Life Science and Technology, Jinan University, Guangzhou 510632, China.
- Department of Medical Genetics, Guangdong Medical University, Dongguan 523808, China.
- Guangdong Province Key Laboratory of Bioengineering Medicine, Guangzhou 510632, China.
- Guangdong Provincial Biotechnology Drug & Engineering Technology Research Center, Guangzhou 510632, China.
- National Engineering Research Center of Genetic Medicine, Guangzhou 510632, China.
ORCID-Profile: Lili Liang
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Guangdong Province
Zitieren
APA
Liang, L., Chen, S., Su, W., Zhang, H., & Yu, R. (2024). Integrated Transcriptomic and Proteomic Study of the Mechanism of Action of the Novel Small-Molecule Positive Allosteric Modulator 1 in Targeting PAC1-R for the Treatment of D-Gal-Induced Aging Mice. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25073872
Vancouver
Liang L, Chen S, Su W, Zhang H, Yu R. Integrated Transcriptomic and Proteomic Study of the Mechanism of Action of the Novel Small-Molecule Positive Allosteric Modulator 1 in Targeting PAC1-R for the Treatment of D-Gal-Induced Aging Mice. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25073872
BibTeX
@article{Liang2024,
author = {Liang, Lili and Chen, Shang and Su, Wanlin and Zhang, Huahua and Yu, Rongjie},
title = {Integrated Transcriptomic and Proteomic Study of the Mechanism of Action of the Novel Small-Molecule Positive Allosteric Modulator 1 in Targeting PAC1-R for the Treatment of D-Gal-Induced Aging Mice},
journal = {International Journal of Molecular Sciences},
year = {2024},
doi = {10.3390/ijms25073872}
}
EUVIMED